Rapid antibiotic-resistance tests

01Overview and value chain

Markers: [EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Rapid antibiotic-resistance tests determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours rather than the 2-3 days conventional culture-based antibiotic susceptibility testing (AST) requires, letting clinicians switch from broad-spectrum empiric therapy to a targeted antibiotic sooner — a direct lever against antimicrobial resistance and unnecessary broad-spectrum antibiotic use. Accelerate Diagnostics’ Accelerate Pheno system runs rapid phenotypic AST directly from a positive blood culture, with its clinical performance documented across multiple peer-reviewed studies. T2 Biosystems’ T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from a blood sample without waiting for culture, with the company continuing to publish clinical-benefit data and advance its product pipeline. Q-linea’s ASTar system runs rapid phenotypic AST directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu. Selux Diagnostics has patented a parallel-processing antimicrobial susceptibility testing system and method, aiming to run many antibiotic-pathogen combinations simultaneously. In China, Autobio Diagnostics (安图生物), a major domestic in-vitro diagnostics company, participates in the country’s antibiotic-susceptibility and broader IVD testing market.

The key directions of rapid antibiotic-resistance tests are:

1. Rapid phenotypic AST from blood culture (Rapid Phenotypic AST): growth-based susceptibility testing run directly from a positive blood culture, returning a full susceptibility profile in hours instead of days — Accelerate Diagnostics’ Accelerate Pheno, Q-linea’s ASTar.
2. Molecular resistance-gene detection (Molecular Resistance Detection): direct-from-blood detection of specific antibiotic-resistance genes without waiting for a positive culture — T2 Biosystems’ T2Resistance Panel.
3. Parallel-processing AST platforms (Parallel Processing AST): engineering approaches that test many antibiotic-pathogen combinations simultaneously to compress overall turnaround time — Selux Diagnostics.
4. Domestic AST/IVD platforms (Domestic AST Platforms): regionally manufactured antibiotic-susceptibility and broader in-vitro diagnostic platforms serving a domestic clinical-microbiology market — Autobio Diagnostics.

Sectoral value chain

[positive blood culture / isolate sample] ──> [rapid AST or molecular resistance-gene analysis] ──> [susceptibility profile / resistance-gene result]
                                                    │
                                       (regulatory clearance: FDA/IVDR/NMPA)
                                                    │
                                                    ▼
[antimicrobial stewardship & outcome tracking] <─── [clinical antibiotic selection decision] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Rapid phenotypic susceptibility testing (Rapid Phenotypic AST): growth-based methods measure whether the pathogen actually grows in the presence of each antibiotic, compressed from days to hours through automated imaging and analysis, as in Accelerate Pheno and Q-linea’s ASTar.
• Magnetic-resonance molecular detection (Molecular Resistance Detection): T2 Biosystems’ magnetic-resonance technology detects resistance genes and pathogen signatures directly from whole blood, bypassing the culture step entirely.
• Parallel antibiotic-pathogen processing (Parallel Processing AST): engineering multiple simultaneous antibiotic-exposure conditions, per Selux Diagnostics’ patented approach, compresses the number of sequential test cycles needed to cover a full antibiotic panel.

02US

The US anchors the deepest bench of rapid AST and molecular resistance-detection companies, spanning phenotypic, molecular and parallel-processing approaches.

Accelerate Pheno, T2Resistance, Selux, FDA

• Accelerate Diagnostics: its Accelerate Pheno system runs rapid phenotypic antibiotic susceptibility testing directly from a positive blood culture, with clinical performance documented across multiple peer-reviewed studies.
• T2 Biosystems: its T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from blood without waiting for culture, continuing to publish clinical-benefit data and advance its product pipeline.
• Selux Diagnostics: has patented a parallel-processing antimicrobial susceptibility testing system and method, aiming to test many antibiotic-pathogen combinations simultaneously to compress turnaround time.
• FDA framework: rapid AST platforms clear the FDA via 510(k)/PMA review as in-vitro diagnostic devices, with each expanded antibiotic or pathogen menu typically requiring its own regulatory clearance.

03CN

China hosts a growing domestic in-vitro diagnostics base for antibiotic susceptibility and broader clinical microbiology testing, with Autobio Diagnostics among the major domestic providers.

Autobio Diagnostics, NMPA

• Autobio Diagnostics (安图生物): a major domestic in-vitro diagnostics company, participates in China’s antibiotic-susceptibility and broader IVD testing market.
• NMPA framework: antibiotic-susceptibility testing platforms and reagents in China require NMPA approval as in-vitro diagnostic products, with domestic manufacturers competing alongside imported rapid-AST platforms.

04EU

Sweden anchors Europe’s rapid AST capacity through Q-linea, which recently secured FDA clearance for an expanded version of its rapid phenotypic testing platform.

Q-linea, ASTar, IVDR

• Q-linea: its ASTar system runs rapid phenotypic antibiotic susceptibility testing directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu, extending the platform’s antibiotic and pathogen coverage.
• IVDR framework: rapid AST platforms sold in the EU require conformity assessment and CE marking under the In Vitro Diagnostic Regulation (IVDR 2017/746), with Q-linea’s home Swedish market operating under this framework alongside its separate FDA clearance for the US.

05Leading companies and research institutes

06Tech stack and innovations

The stack spans three distinct technical routes to the same goal — a susceptibility or resistance result in hours rather than days — phenotypic growth-based testing, molecular resistance-gene detection, and engineered parallel processing.

1. Rapid phenotypic AST (Rapid Phenotypic AST):
   • Accelerate Diagnostics’ Accelerate Pheno and Q-linea’s ASTar both run automated, imaging-based growth assessment directly from a positive blood culture, compressing conventional 2-3-day susceptibility testing into hours.
2. Molecular resistance-gene detection (Molecular Resistance Detection):
   • T2 Biosystems’ T2Resistance Panel applies magnetic-resonance technology to detect resistance genes directly from whole blood, bypassing the culture-growth step that phenotypic methods still require.
3. Parallel antibiotic-pathogen processing (Parallel Processing AST):
   • Selux Diagnostics’ patented system and method run many antibiotic-pathogen exposure conditions simultaneously, engineering around the sequential-testing bottleneck that limits how fast a full antibiotic panel can be completed.
4. Domestic AST manufacturing (Domestic AST Platforms):
   • Autobio Diagnostics manufactures antibiotic-susceptibility and broader in-vitro diagnostic platforms for China’s domestic clinical-microbiology market.

07Value chains and production pipelines

Industrial pipeline of a rapid antibiotic-resistance test (FDA 510(k)/PMA / EU IVDR 2017/746)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sample input           │ ───> │ 2. Rapid AST / molecular  │
│    (positive culture)      │      │    analysis                 │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Regulatory clearance   │ <─── │ 3. Result generation      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Clinical antibiotic    │ ───> │ 6. Antimicrobial          │
│    selection                │      │    stewardship               │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Sample input

A positive blood culture (Accelerate Pheno, ASTar, T2Resistance) or clinical isolate identifying the infecting pathogen enters the rapid-testing workflow.

Stage 2: Rapid AST or molecular analysis

The platform runs phenotypic growth-based susceptibility testing across a panel of antibiotics, or molecular detection of specific resistance genes, depending on whether it follows the phenotypic (Accelerate Diagnostics, Q-linea) or molecular (T2 Biosystems) approach.

Stage 3: Result generation

The platform reports a susceptibility profile (susceptible/intermediate/resistant per antibiotic tested) or a resistance-gene detection call, typically within hours of sample input.

Stage 4: Regulatory clearance

The AST platform and each antibiotic or pathogen menu clears FDA 510(k)/PMA review, EU IVDR conformity assessment, or NMPA registration, with expanded menus (such as Q-linea’s 2026 ASTar expansion) requiring their own clearance.

Stage 5: Clinical antibiotic selection

The treating physician uses the rapid result to switch from broad-spectrum empiric therapy to a targeted antibiotic hours or days sooner than conventional culture-based AST would allow.

Stage 6: Antimicrobial stewardship

Hospital antimicrobial-stewardship programs track prescribing patterns and resistance trends enabled by faster, more targeted antibiotic selection, closing the loop between rapid diagnostics and reduced unnecessary broad-spectrum antibiotic use.